Bio-Path Holdings, Inc. (NASDAQ:BPTH)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Monday, MarketBeat Ratings reports. They presently have a $1.50 price target on the stock, down from their previous price target of $4.50. HC Wainwright’s target price would suggest a potential upside of 383.87% from the stock’s previous close.
Separately, ValuEngine downgraded Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Bio-Path Holdings (BPTH) opened at $0.31 on Monday. Bio-Path Holdings has a twelve month low of $0.25 and a twelve month high of $1.50.
Bio-Path Holdings (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). research analysts forecast that Bio-Path Holdings will post -0.08 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/13/hc-wainwright-reaffirms-buy-rating-for-bio-path-holdings-inc-bpth.html.
Several hedge funds have recently bought and sold shares of the business. Legal & General Group Plc grew its holdings in shares of Bio-Path Holdings by 5,474.3% during the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after acquiring an additional 1,741,978 shares during the period. HighTower Advisors LLC grew its holdings in shares of Bio-Path Holdings by 0.3% during the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after acquiring an additional 4,000 shares during the period. Sabby Management LLC grew its holdings in shares of Bio-Path Holdings by 73.2% during the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock worth $462,000 after acquiring an additional 503,488 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Bio-Path Holdings by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after acquiring an additional 5,172 shares during the period. Hedge funds and other institutional investors own 15.15% of the company’s stock.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.